Effect of probenecid on the renal excretion mechanism of a new carbapenem, DA-1131, in rats and rabbits

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 1, 1999, Pages 96-99

  Kim, So H ^a   Kim, Won B ^b   Lee, Myung G ^a  

^a Seoul National University   (South Korea)

^b Dong A Pharmaceutical Company   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

6 (1 HYDROXYETHYL) 2 [2 (3 METHANESULFONYLAMINO 1 PROPENYL) 4 PYRROLIDINYLTHIO] 1 METHYL 1 CARBAPEN 2 EM 3 CARBOXYLIC ACID; ANTIBIOTIC AGENT; CARBAPENEM; PROBENECID;

ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; GLOMERULUS FILTRATION RATE; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY METABOLISM; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT; URINARY EXCRETION;

EID: 0032906699     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.1.96     Document Type: Article

References (23)

1. Bax, R. P., W. Bastain, A. Featherstone, D. M. Wilkinson, M. Hutchison, and S. J. Haworth. 1989. The pharmacokinetics of meropenem in volunteers. J. Antimicrob. Chemother. 24(Suppl. A):311-320.
2. Chiou, W. L. 1978. Critical evaluation of potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J. Pharmacokinet. Biopharm. 6:539-546.
3. Chiou, W. L. 1979. New calculation method for mean apparent drug volume of distribution and application to rationale dosage regimens. J. Pharm. Sci. 68:1067-1069.
4. Chiou, W. L. 1980. New calculation method of mean total body clearance of drugs and its application to dosage regimens. J. Pharm. Sci. 69:90-91.
5. Davies, B., and T. Morris. 1995. Physical parameters in laboratory animals and humans. Pharm. Res. 7:1093-1095.
6. Drusano, G. L. 1986. An overview of the pharmacology of imipenem/cilastatin. J. Antimicrob. Chemother. 18(Suppl. E):79-92.
7. Drusano, G. L., and H. C. Standiford. 1985. Pharmacokinetic profile of imipenem/cilastatin in normal volunteers. Am. J. Med. 78(Suppl. 6A):47-53.
8. Drusano, G. L., H. C. Standiford, C. Bustamante, A. Forrest, G. Rivera, J. Leslie, B. Tatem, D. Delaportas, R. R. MacGregor, and S. C. Schimpff. 1984. Multiple-dose pharmacokinetics of imipenem/cilastatin. Antimicrob. Agents Chemother. 26:715-721.
9. Eatman, F. B., W. A. Colburn, H. G. Boxenbaum, H. N. Posmanter, R. E. Weinfeld, R. Ronfeld, L. Weissman, J. D. Moore, M. Gibaldi, and S. A. Kaplan. 1977. Pharmacokinetics of diazepam following multiple dose oral administration to healthy human subjects. J. Pharmacokinet. Biopharm. 5: 481-494.
10. Fukuda, Y., T. Muratani, M. Takahata, Y. Fukuoka, T. Tasuda, Y. Watanabe, and H. Narita. 1995. Mechanism of renal excretion of T-3761, a novel fluoroquinolone agent, in rabbits. Jpn. J. Antibiot. 48:649-655.
11. Gibaldi, M., and D. Perrier. 1982. Pharmacokinetics, 2nd ed. Marcel Dekker, Inc., New York, N.Y.
12. Kim, G. W., M. S. Chang, K. W. Lee, Y. S. Chong, and J. Yang. 1996. Comparative in vitro antibacterial activity of DA-1131, a new carbapenem antibiotic (I), abstr., p. 232. In Abstracts of the Annual Meeting of the Korea Society of Applied Pharmacology.
13. Kim, J. Y., G. W. Kim, S. H. Choi, J. S. We. H. S. Park, and J. Yang. 1996. Renal dehydropeptidase-I (DHP-I) stability and pharmacokinetics of DA-1131, a new carbapenem antibiotic, abstr., p. 238. In Abstracts of the Annual Meeting of the Korea Society of Applied Pharmacology.
14. Kim, S. H., Y. M. Choi, and M. G. Lee. 1993. Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J. Pharmacokinet. Biopharm. 21:1-17.
15. Kim, S. H., W. B. Kim, and M. G. Lee. 1995. Stability, tissue metabolism, tissue distribution, and blood partition of DA-1131, a new carbapenem. Res. Commun. Mol. Pathol. Pharmacol. 90:347-362.
16. Kim, S. H., W. B. Kim, and M. G. Lee. 1997. Pharmacokinetics of a new carbapenem, DA-1131, after intravenous administration to rabbits with endotoxin-induced pyrexia. Res. Commun. Pharmacol. Toxicol. 2:121-128.
17. Kim, S. H., W. B. Kim, and M. G. Lee. 1998. Interspecies pharmacokinetic scaling of a new carbapenem, DA-1131, in mice, rats, rabbits, and dogs, and prediction of human pharmacokinetics. Biopharm. Drug Dispos. 19:231-235.
18. Kim, S. H., W. B. Kim, and M. G. Lee. 1998. Pharmacokinetics of a new carbapenem, DA-1131, after intravenous administration to rats with alloxan-induced diabetes mellitus. Biopharm. Drug Dispos. 19:303-308.
19. Kim, S. H., J. W. Kwon, and M. G. Lee. 1998. Pharmacokinetics and tissue distribution of a new carbapenem, DA-1131, after intravenous administration to mice, rats, rabbits, and dogs. Biopharm. Drug Dispos. 19:219-229.
20. Kim, S. H., J. W. Kwon, J. Yang, and M. G. Lee. 1997. Determination of a new carbapenem derivative, DA-1131, in plasma and urine by high-performance liquid chromatography. J. Chromatogr. Ser. B 688:95-99.
21. Kim, S. H., H. J. Shim, W. B. Kim, and M. G. Lee. 1998. Pharmacokinetics of a new carbapenem, DA-1131, after intravenous administration to rats with uranyl nitrate-induced acute renal failure. Antimicrob. Agents Chemother. 42:1217-1221.
22. Nadai, M., R. Apichartpichean, T. Hasegawa, and T. Nabeshima. 1992. Pharmacokinetics and the effect of probenecid on the renal excretion mechanism of diprophylline. J. Pharm. Sci. 81:1024-1027.
23. Ram, A., D. Glaubiger, N. P. Ramu, N. Eldridge, and T. F. Blaschke. 1978. Probenecid inhibition of methotrexate excretion from cerebrospinal fluid in dogs. J. Pharmacokinet. Biopharm. 6:389-397.